XML 93 R69.htm IDEA: XBRL DOCUMENT v3.22.4
ACQUISITIONS AND OTHER ARRANGEMENTS (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2022
Aug. 31, 2022
Jun. 30, 2022
May 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Apr. 30, 2021
Jul. 03, 2015
Business Acquisition [Line Items]                    
Payment for acquisition options           $ 109,600,000 $ 13,100,000 $ 10,000,000.0    
Carrying value of non-marketable equity securities         $ 84,100,000 86,900,000 84,100,000      
Kardion, Inc.                    
Business Acquisition [Line Items]                    
Carrying value of non-marketable equity securities                 $ 35,900,000  
Investment option to acquire                 5,700,000  
Maximum additional option to acquire investment                 21,800,000  
Investment after first milestone         $ 10,800,000          
Maximum secured promissory note                 45,000,000  
Secured promissory note           0        
Kardion, Inc. | Equity Securities                    
Business Acquisition [Line Items]                    
Maximum additional required investment                 $ 9,900,000  
Variable Interest Entity, Not Primary Beneficiary | Medical Device Company                    
Business Acquisition [Line Items]                    
Payment for acquisition options   $ 47,100,000 $ 35,000,000              
Option to acquire investment amount   $ 47,100,000       35,000,000        
Loans receivables, maximum lending amount     $ 47,500,000              
Financing receivable           32,500,000        
Variable Interest Entity, Not Primary Beneficiary | Medical Technology Company                    
Business Acquisition [Line Items]                    
Payment for acquisition options       $ 60,000,000     10,000,000      
Option to acquire investment amount       $ 60,000,000            
In-process Research and Development                    
Business Acquisition [Line Items]                    
Impairment charges           $ 52,700,000 $ 0 $ 0    
Harpoon Medical | In-process Research and Development                    
Business Acquisition [Line Items]                    
Impairment charges $ 28,100,000                  
CardiAQ                    
Business Acquisition [Line Items]                    
Additional research and development expenditures to be incurred prior to product introduction                   $ 97,700,000